Explore

Rapid Read Rapid Read
Japanese Fruit Sarunashi Shows Potential in Preventing Lung Cancer in Mice

Japanese Fruit Sarunashi Shows Potential in Preventing Lung Cancer in Mice

Researchers at Okayama University have identified a small Japanese fruit, Sarunashi (Actinidia arguta), also known as the kiwiberry, as a potential agent in preventing lung cancer. In a study published in the journal Genes and Environment, the fruit's juice was found to reduce lung tumor formation in mice exposed to NNK, a carcinogen related to tobacco. The juice also decreased the number of tumor nodules in the lungs, and its compound isoquercetin demonstrated protective effects. The study suggests that Sarunashi juice may interfere with the initiation and growth of cancer by reducing DNA damage and supporting DNA repair mechanisms. While these findings are promising, clinical trials are necessary to confirm the fruit's efficacy in humans.
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026
Rapid Read Rapid Read
Research Highlights Impact of Insurance on Cancer Survival Among Young Adults

Research Highlights Impact of Insurance on Cancer Survival Among Young Adults

Recent research underscores the significant role that insurance status plays in cancer survival rates among young adults in the United States. A comprehensive review of scientific literature, involving nearly 470,000 Americans aged 15 to 39 diagnosed with cancer, reveals that those with private health insurance have a survival advantage over those on Medicaid or without insurance. This advantage varies by cancer type, with private insurance reducing the risk of death by 8% for lymphoma and up to 2.5 times for melanoma and other cancers. The study highlights the instability of health coverage for young adults, who often lose insurance when they turn 26 or start jobs without benefits, leaving many uninsured or underinsured. This instability exacerbates the already slower improvements in cancer survival rates for this age group compared to children and older adults.
Trendline Trendline
U.S. Administration Imposes 100% Tariffs on Branded Pharmaceutical Imports, Impacting Global Healthcare

U.S. Administration Imposes 100% Tariffs on Branded Pharmaceutical Imports, Impacting Global Healthcare

U.S. Administration Imposes 100% Tariffs on Branded Pharmaceutical Imports, Impacting Global Healthcare
Rapid Read Rapid Read
Vitamin B3 Supplements May Undermine Cancer Treatment, Study Warns

Vitamin B3 Supplements May Undermine Cancer Treatment, Study Warns

A study from Case Western Reserve University has raised concerns about the use of NAD+ boosting supplements, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), in cancer treatment. These supplements, popular for their energy-boosting and anti-aging claims, may inadvertently aid cancer cell survival during chemotherapy. The research, published in Cancer Letters, indicates that these supplements can enhance the energy production of cancer cells, reduce oxidative stress, and limit DNA damage, thereby making tumors more resistant to chemotherapy. The study specifically highlights the impact on pancreatic cancer cells, which are notoriously difficult to treat.
Rapid Read Rapid Read
Innovative Therapy Shows Promise in Halting Prostate Cancer Spread to Bone

Innovative Therapy Shows Promise in Halting Prostate Cancer Spread to Bone

Researchers at the VCU Massey Comprehensive Cancer Center have developed a new targeted therapy that effectively prevents prostate cancer from spreading to the bones. The therapy, involving a small molecule inhibitor called IVMT-Rx-4, has shown promising results in preclinical models by blocking the function of a gene known as MDA-9/syntenin, which is responsible for tumor growth and metastasis. This innovative approach not only halts the progression of prostate cancer to an advanced stage but also enhances the efficacy of existing chemotherapy treatments. The findings, published in Pharmacological Research, suggest a potential paradigm shift in treating metastatic prostate cancer.
Trendline Trendline
AvenCell Therapeutics Initiates Phase I Study of Novel CAR-T Therapy for B-Cell Malignancies

AvenCell Therapeutics Initiates Phase I Study of Novel CAR-T Therapy for B-Cell Malignancies

AvenCell Therapeutics Initiates Phase I Study of Novel CAR-T Therapy for B-Cell Malignancies
Rapid Read Rapid Read
University of Colorado Anschutz Gains FDA Clearance for CAR T-Cell Therapy

University of Colorado Anschutz Gains FDA Clearance for CAR T-Cell Therapy

The University of Colorado Anschutz Gates Institute has achieved a significant milestone by receiving FDA clearance for a new CAR T-cell therapy developed entirely on its campus. This therapy targets the CD64 protein on leukemia cells and is designed for patients with relapsed or refractory acute myeloid leukemia (AML). The clearance marks the first time a CAR T-cell therapy developed on a university campus has been authorized for clinical testing in the U.S. The Phase 1 clinical trial will begin in June 2026, focusing on evaluating the safety and optimal dosing of the therapy in adults with AML. This development is the result of years of research and collaboration among scientists, clinicians, and regulatory teams at the Gates Institute.
Rapid Read Rapid Read
FDA Selects Wugen's Soficabtagene Geleucel for CMC Development Pilot Program

FDA Selects Wugen's Soficabtagene Geleucel for CMC Development Pilot Program

The U.S. Food and Drug Administration (FDA) has chosen Wugen, Inc.'s investigational therapy, Soficabtagene Geleucel (Sofi-cel), to participate in its Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. This program is designed to support the manufacturing readiness of therapies with expedited clinical development timelines. Sofi-cel is an allogeneic, anti-CD7 CAR-T cell therapy currently under evaluation in a pivotal trial for patients with relapsed or refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma. The FDA's selection allows Wugen to engage more frequently with the agency on CMC strategy, facilitating the therapy's advancement towards a Biologics License Application (BLA) submission. Sofi-cel has already received multiple designations from the FDA, including Breakthrough Therapy and Regenerative Medicine Advanced Therapy, which aim to expedite the development of promising therapies.
Rapid Read Rapid Read
Epigenetic Strategy Shows Promise in Treating Acute Myeloid Leukemia

Epigenetic Strategy Shows Promise in Treating Acute Myeloid Leukemia

Researchers from The Jackson Laboratory have developed an epigenetic strategy to reactivate a tumor suppressor gene, ZBTB7A, in acute myeloid leukemia (AML) models. This approach involves inhibiting KDM4 enzymes, which are responsible for silencing the gene in AML cells. By restoring ZBTB7A expression, the researchers were able to reduce the aggressiveness of cancer cells in mice, potentially offering a less toxic alternative to chemotherapy. The study, published in Science Translational Medicine, highlights the potential for repurposing existing drug candidates to inhibit KDM4 and treat AML without harming normal blood cells.
Rapid Read Rapid Read
FDA Classifies Nationwide Eye Drop Recall Due to Sterility Concerns

FDA Classifies Nationwide Eye Drop Recall Due to Sterility Concerns

The U.S. Food and Drug Administration (FDA) has classified a nationwide recall of over 3.1 million bottles of eye drops as a Class II recall, following sterility concerns. The recall, initiated by K.C. Pharmaceuticals, involves a range of over-the-counter eye drop products distributed under various brand names through major retailers like Walgreens, Kroger, and CVS. The FDA's Class II designation indicates that the use of these products may cause temporary or medically reversible adverse health consequences. The recall remains ongoing, with no termination date set, as the FDA continues to assess the situation.
Rapid Read Rapid Read
Comparison of New Weight Loss Pills: Foundayo and Wegovy

Comparison of New Weight Loss Pills: Foundayo and Wegovy

The weight loss medication landscape has expanded with the introduction of two new GLP-1 pills: Wegovy and Foundayo. Wegovy, developed by Novo Nordisk, is an FDA-approved oral semaglutide medication designed for adults with overweight or obesity. It mimics the glucagon-like peptide 1 (GLP-1) to reduce hunger and slow food transit in the gut, helping users feel fuller longer. Foundayo, or orforglipron, created by Lilly, also mimics GLP-1 but is a small molecule rather than a peptide, allowing it to survive digestion without injections or strict fasting protocols. Both medications require starting at a lower dose before increasing to higher doses, and they offer alternatives to injectable weight loss treatments.